Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742801 · ClinicalTrials.gov registry record · NA
Onyx™ Liquid Embolic IDE Clinical Study
A NA study of Trauma and Hemorrhage, sponsored by Medtronic Endovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 119
- Enrollment target
- 14
- Study locations
NCT06742801: Recruiting NA study of Trauma and Hemorrhage, sponsored by Medtronic Endovascular.
NCT06742801 is a NA study of Trauma and Hemorrhage that is actively recruiting participants, run by Medtronic Endovascular. The registered enrollment target is 119 participants, below the 305-participant average among 56 other Trauma trials with a reported enrollment target (61% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742801, a NA study of Trauma and Hemorrhage, is actively recruiting participants, sponsored by Medtronic Endovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Primary Outcome
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days.
Conditions Studied
Interventions
- DEVICE Onyx™ Liquid Embolic System
Study Locations (14)
California
- University of California, Irvine - Irvine
- Stanford Medical Center - Palo Alto
New York
- Albany Medical Center - Albany
- The Mount Sinai - New York
Texas
- Univ Of Texas Southwestern - Dallas
- The University of Texas Health Science Center at Houston - Houston
Arizona
- Mayo Clinic - Phoenix
Colorado
- UCHealth University of Colorado Hospital - Aurora
Connecticut
- Yale New Haven - New Haven
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- Masschusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06742801 shows while recruiting
NCT06742801 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 305-participant average among 56 other Trauma trials with a reported enrollment target (61% lower).
The record links to 5 conditions, with Trauma appearing as the primary indexed condition, and to 1 intervention - of which Onyx™ Liquid Embolic System is the first listed.
NCT06742801 lists 14 locations in 11 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT06742801 about?
NCT06742801 is a clinical study titled "Onyx™ Liquid Embolic IDE Clinical Study". The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
What is the current status of trial NCT06742801?
This trial is currently recruiting. It is a NA study. The enrollment target is 119 participants. The study started on 2025-05-09. Estimated completion is 2026-12.
What conditions does trial NCT06742801 study?
This clinical trial studies the following conditions: Trauma, Hemorrhage, Ulcer, GI Bleed, Peripheral Arterial Hemorrhage.
What interventions are being tested in trial NCT06742801?
The interventions under investigation include: Onyx™ Liquid Embolic System (DEVICE).
Who is sponsoring clinical trial NCT06742801?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742801 being conducted?
This trial has 14 study locations across Arizona, California, Colorado, Connecticut, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06742801's enrollment target sits among peer trials
119 28th of 56 higher than 29 of 56 other Trauma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Trauma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing FIRST in Youth Outpatient Psychotherapy
RECRUITING · NA
-
PRESERVE & CONNECT: Impact Study of the BPC
RECRUITING · NA
-
Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)
RECRUITING · NA
-
Evaluation of the Parenting in the Moment Online Program for Forcibly Displaced Families
RECRUITING · NA
-
RCT: Early Feeding After PEG Placement
RECRUITING · NA
-
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06930625 · 119 participants · Phase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI